Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234999 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Study of CC-122 in Healthy Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02234999: Completed Phase 1 study, sponsored by Celgene.
NCT02234999 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234999, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects
Primary Outcome
Biological matrices (whole blood, plasma, urine and feces) will be collected and analyzed for total \[14C\]-radioactivity
Interventions
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09-23 |
| Est. Completion | 2014-10-08 |
| Phase | Phase 1 |
What the finished NCT02234999 record still lists
NCT02234999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which CC-122 is the first listed.
NCT02234999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02234999 about?
NCT02234999 is a clinical study titled "Radiolabeled Study of CC-122 in Healthy Subjects". To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects
What is the current status of trial NCT02234999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-09-23. Estimated completion is 2014-10-08.
What interventions are being tested in trial NCT02234999?
The interventions under investigation include: CC-122 (DRUG).
Who is sponsoring clinical trial NCT02234999?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02234999's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI